Metastatic Melanoma Pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Melanoma treatment therapies, analyzes DelveInsight.
Metastatic Melanoma Overview:
Melanoma is the third most prevalent type of skin cancer, following basal cell and squamous cell carcinoma. It ranks as the fifth most common cancer in men and sixth in women. Metastatic melanoma refers to the spread of malignant cells from the original tumor to other parts of the body, typically occurring in stage 3 or 4. Common sites of metastasis include the lymph nodes, lungs, liver, bones, and brain. Symptoms depend on the area affected and may include fatigue, enlarged lymph nodes, weight loss, difficulty breathing, bone pain, and neurological complications.
Diagnosis typically starts with a physical skin examination and a biopsy—such as punch, excisional, or shave—to determine tumor thickness. If metastasis is suspected, further tests like lymph node mapping, CT scans, PET scans, MRI, ultrasound, and blood chemistry panels are used to assess the spread.
Treating metastatic melanoma is difficult, with a five-year survival rate of around 66% when the cancer has spread to nearby lymph nodes and only 27% when it reaches distant organs. As undetectable metastases can occur, the prognosis worsens with disease progression.
Request for a detailed insights report on Metastatic Melanoma pipeline insights
"Metastatic Melanoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Metastatic Melanoma Therapeutics Market.
Key Takeaways from the Metastatic Melanoma Pipeline Report
-
DelveInsight’s Metastatic Melanoma pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Melanoma treatment.
-
In October 2025, Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company specializing in T cell-redirecting cancer immunotherapies, announced updated Phase 1b clinical data for ACTengine® IMA203 TCR-T, which targets PRAME in melanoma patients. Additionally, the company provided insights into SUPRAME, an upcoming Phase 3 trial aimed at evaluating IMA203 in metastatic melanoma patients.
-
In April 2025, Obsidian Therapeutics provided an update on its Phase I first-in-human study of OBX-115, a tumor-infiltrating lymphocyte (TIL) cell therapy for individuals with advanced or metastatic melanoma. Presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, the update included safety data from a median 25-week study follow-up along with detailed efficacy results.
-
Iin April 2025, Iovance Biotherapeutics announced that clinical data on lifileucel in combination with pembrolizumab for frontline advanced melanoma, along with translational data, will be presented at the 2025 ASCO Annual Meeting.
-
Key Metastatic Melanoma companies such as Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, and others are evaluating new drugs for Metastatic Melanoma to improve the treatment landscape.
-
Promising Metastatic Melanoma pipeline therapies in various stages of development include EVX 01, IN 10018, AV MEL 1, and others.
Metastatic Melanoma Pipeline Analysis
The report provides insights into:
-
The report provides detailed insights into the key companies that are developing therapies in the Metastatic Melanoma Market.
-
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Melanoma treatment.
-
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Metastatic Melanoma market.
Download our free sample page report on Metastatic Melanoma pipeline insights
Metastatic Melanoma Emerging Drugs
-
EVX 01: Evaxion Biotech
-
IN 10018: InxMed
-
AV MEL 1: AiVita Biomedical
Metastatic Melanoma Companies
More than 75 leading companies are actively developing treatments for metastatic melanoma. Among these, Evaxion Biotech has a drug candidate that is the furthest along in development, currently in Phase II clinical trials.
DelveInsight’s report covers around 75+ products under different phases of clinical development like
-
Late stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I) along with the details of
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Metastatic Melanoma Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Metastatic Melanoma Therapies and Key Companies: Metastatic Melanoma Clinical Trials and advancements
Metastatic Melanoma Pipeline Therapeutic Assessment
• Metastatic Melanoma Assessment by Product Type
• Metastatic Melanoma By Stage
• Metastatic Melanoma Assessment by Route of Administration
• Metastatic Melanoma Assessment by Molecule Type
Download Metastatic Melanoma Sample report to know in detail about the Metastatic Melanoma treatment market @ Metastatic Melanoma Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Metastatic Melanoma Current Treatment Patterns
4. Metastatic Melanoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Metastatic Melanoma Late-Stage Products (Phase-III)
7. Metastatic Melanoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Metastatic Melanoma Discontinued Products
13. Metastatic Melanoma Product Profiles
14. Metastatic Melanoma Key Companies
15. Metastatic Melanoma Key Products
16. Dormant and Discontinued Products
17. Metastatic Melanoma Unmet Needs
18. Metastatic Melanoma Future Perspectives
19. Metastatic Melanoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Metastatic Melanoma Pipeline Reports Offerings
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
